Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety and Tolerance of a Novel Three-Strain Probiotic in Healthy Adults

6 maj 2026 uppdaterad av: Pendulum Therapeutics

A Two-Phase Study on the Safety and Tolerance of a Novel Probiotic in Healthy Adults: Open-Label and Double-Blind, Placebo-Controlled Study

This Phase I & II study evaluates the safety and tolerability of 8 weeks of daily supplementation with high-dose versus standard-dose of a novel three-strain probiotic. Safety and tolerability will be assessed by adverse events, safety blood profile, and vital signs. Secondary assessments include food cravings, gastrointestinal outcomes, sleep, quality of life, subjective ratings of hunger and satiety and associated hormone responses including plasma GLP-1, glucose, and insulin.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

A Two-Phase Study safety and tolerance study:

Phase I: Open-Label Study Phase II: Randomised Double-Blind, Placebo-Controlled Study

Studietyp

Interventionell

Inskrivning (Faktisk)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Cork, Irland
        • Atlantia Clinical Trials

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

To be eligible for inclusion, the Participant must fulfill all the following criteria:

  1. Be able to give written informed consent.
  2. Be between 18 and 65 years, inclusive.
  3. Has a BMI: Phase I ≤29.9kg/m2. Phase II ≤34.9kg/m2.
  4. Mean total food craving score (FCI-UK) of ≥2.5 at screening visit. (Phase I only) 5. Stable weight for the past 30 days (defined as ± 2.3kg).

6. Willing to consume the Study Product daily for the duration of the study.

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

  1. Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
  2. Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:

    1. Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).
    2. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that Participant.
    3. Sexual partner(s) is/are exclusively female.
    4. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.
    5. Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.
  3. Has food allergies or other issues with foods that would preclude intake of the Study Products.

    1. Known hypersensitivity to any component of the probiotic used in the study (Clostridium butyricum WB-STR-0006, Akkermansia muciniphila WB-STR-0001, Bifidobacterium infantis, chicory inulin, microcrystalline cellulose, l-leucine, hypromellose (vegetarian capsule), silica)
    2. Known hypersensitivity or allergy to any component of the meal product used in the meal challenge (allergens: milk and soy)
  4. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include: a. Gastrointestinal condition (including GI bleeding in the past 3 months) b. Major gastrointestinal surgery or explorations (cholecystectomy and appendectomy are allowed) c. Cancer (in the past 1 year) d. Active autoimmune condition e. Cardiovascular disease (in the past 3 months) 5. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include: a. Oral antibiotics or Antifungals (in the past 1 month) b. Medications impacting gut motility (in the 2 weeks prior to baseline) c. GLP-1 receptor agonists (in the past 6 months) d. Sulfonylureas (in the past 6 months) e. Proton Pump Inhibitors (in the past 1 month) f. Laxatives (in the past 1 month)

6. Current or recent (in the past 1 month) use of prohibited nutritional or non-nutritional supplements, including:

  1. Probiotics/Prebiotics
  2. Fibre supplements 7. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.

    8. Participants may not be receiving treatment involving experimental drugs/supplements. If the Participant has been in a recent experimental study, these must have been completed not less than 90 days for drugs and 30 days for supplements prior to this study.

    9. Current participation or planned participation in a weight loss program during the study period 10. Known hypersensitivity to >4 first-line antimicrobial therapies against Akkermansia muciniphila: Penicillin, Piperacillin, Amoxicillin, Ampicillin, Tetracycline 11. Known hypersensitivity to >4 first-line antimicrobial therapies against Clostridium butyricum: Penicillin, Piperacillin, Amoxicillin, Ampicillin, Tetracycline, Vancomycin, Cefoxitin 12. Known hypersensitivity to >4 first-line antimicrobial therapies against Bifidobacterium infantis Bi-26TM: Gentamicin, Kanamycin, Streptomycin, Tetracycline, Erythromycin, Clindamycin, Ampicillin, Vancomycin

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Phase 1 - Standard Dose
1 capsule
≥ 500 million AFU of Clostridium butyricum strain WB-STR-0006, Akkermansia muciniphila strain WB-STR-0001, Bifidobacterium infantis Bi-26TM, 174 mg chicory inulin (prebiotic), 19mg Microcrystalline Cellulose MCC, 4mg L-Leucine, and 3mg Silica (excipients) to be taken once daily with food
Aktiv komparator: Phase 1 - High Dose
2 capsules
≥ 500 million AFU of Clostridium butyricum strain WB-STR-0006, Akkermansia muciniphila strain WB-STR-0001, Bifidobacterium infantis Bi-26TM, 174 mg chicory inulin (prebiotic), 19mg Microcrystalline Cellulose MCC, 4mg L-Leucine, and 3mg Silica (excipients) to be taken once daily with food
Aktiv komparator: Phase 2 - Active
Dose selected from Phase 1
≥ 500 million AFU of Clostridium butyricum strain WB-STR-0006, Akkermansia muciniphila strain WB-STR-0001, Bifidobacterium infantis Bi-26TM, 174 mg chicory inulin (prebiotic), 19mg Microcrystalline Cellulose MCC, 4mg L-Leucine, and 3mg Silica (excipients) to be taken once daily with food
Placebo-jämförare: Phase 2 - Placebo
Phase 2 - Matching Placebo

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase 1 - Safety and Tolerability - As assessed by Occurrence of Adverse of Events
Tidsram: 8 weeks
Phase I: To evaluate the safety and tolerability of 8-week daily supplementation of high-dose versus standard dose Three-Strain Probiotic as assessed by Occurrence of any Adverse Events Change from baseline to week 8.
8 weeks
Phase 2 - Safety and Tolerability - As assessed by Occurrence of Adverse of Events
Tidsram: 8 weeks
Phase 2: To evaluate the safety and tolerability of 8-week daily supplementation of the selected dose (from Phase I) Three-Strain Probiotic as assessed by Occurrence of any Adverse Events Change from baseline to week 8
8 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Phase 1 - Safety - Blood Biomarkers - Red Blood Cell Count
Tidsram: 8 weeks
(10e12/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - White Blood Cell Count
Tidsram: 8 weeks
(10e9/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Hemoglobin
Tidsram: 8 weeks
(g/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Alanine Aminotransferase
Tidsram: 8 weeks
(IU/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Aspartate Aminotransferase
Tidsram: 8 weeks
(IU/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Serum Creatinine
Tidsram: 8 weeks
(umol/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - eGFR
Tidsram: 8 weeks
(mL/min/1.73 m²)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Sodium
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Potassium
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Total Cholesterol
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - LDL Cholesterol
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - HDL Cholesterol
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 1 - Safety - Blood Biomarkers - LDL:HDL Cholesterol Ratio
Tidsram: 8 weeks
(no units)
8 weeks
Phase 1 - Safety - Blood Biomarkers - Fasting Glucose
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 1 - Vital signs - Systolic Blood Pressure
Tidsram: 8 weeks
mmHG
8 weeks
Phase 1 - Vital signs - Diastolic Blood Pressure
Tidsram: 8 weeks
mmHG
8 weeks
Phase 1 - Vital signs - Heart Rate
Tidsram: 8 weeks
bpm
8 weeks
Phase 1 - Vital signs - Temperature
Tidsram: 8 weeks
˚C
8 weeks
Phase 1 - Total Food Cravings - Food Cravings Inventory (FCI-UK)
Tidsram: 8 weeks
The Food Craving Inventory (FCI-UK) is a UK-specific version of the Food Craving Inventory designed to measure the frequency of cravings for specific foods over the past month. The questionnaire lists 27 food items and generates total food cravings scores.
8 weeks
Phase 1 - Food Cravings - Food Cravings Questionnaire-Trait-reduced (FCQ-T-r)
Tidsram: 8 weeks
The Food Cravings Questionnaire- Trait- reduced (FCQ-T-r) is a 15-item reduced version of the Food Cravings Questionnaire (FCQ). Items included in the FCQ-T-r from the original version subscales include lack of control overeating (5 items), thoughts or preoccupation with food (5 items), intentions and plans to consume food (2 items), emotions before or during food craving (2 items), and cues that may trigger food craving (1 item). Participants indicate on a 6-point scale from 'never/not applicable to always' how frequently each of the 15 statements relating to food cravings is true for them.
8 weeks
Phase 1 - Meal Tolerance Test - Plasma GLP-1 (Total)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in pg/ml.
8 weeks
Phase 1 - Meal Tolerance Test - Plasma Glucose
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in mmol/L.
8 weeks
Phase 1 - Meal Tolerance Test - Satiety (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 1 - Meal Tolerance Test - Hunger (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 1 - Meal Tolerance Test - Fullness (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 1 - Meal Tolerance Test - Desire to eat (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 1 - Weight
Tidsram: 8 weeks
kg
8 weeks
Phase 1 - BMI
Tidsram: 8 weeks
kg/m2
8 weeks
Phase 2 - Vital signs - Systolic Blood Pressure
Tidsram: 8 weeks
mmHG
8 weeks
Phase 2 - Vital signs - Diastolic Blood Pressure
Tidsram: 8 weeks
mmHG
8 weeks
Phase 2 - Vital signs - Heart Rate
Tidsram: 8 weeks
bpm
8 weeks
Phase 2 - Vital signs - Temperature
Tidsram: 8 weeks
˚C
8 weeks
Phase 2 - Total Food Cravings - Food Cravings Inventory (FCI-UK)
Tidsram: 8 weeks
The Food Craving Inventory (FCI-UK) is a UK-specific version of the Food Craving Inventory designed to measure the frequency of cravings for specific foods over the past month. The questionnaire lists 27 food items and generates total food cravings scores.
8 weeks
Phase 2 - Food Cravings - Food Cravings Questionnaire-Trait-reduced (FCQ-T-r)
Tidsram: 8 weeks
The Food Cravings Questionnaire- Trait- reduced (FCQ-T-r) is a 15-item reduced version of the Food Cravings Questionnaire (FCQ). Items included in the FCQ-T-r from the original version subscales include lack of control overeating (5 items), thoughts or preoccupation with food (5 items), intentions and plans to consume food (2 items), emotions before or during food craving (2 items), and cues that may trigger food craving (1 item). Participants indicate on a 6-point scale from 'never/not applicable to always' how frequently each of the 15 statements relating to food cravings is true for them.
8 weeks
Phase 2 - Meal Tolerance Test - Plasma GLP-1 (Total)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in pg/ml.
8 weeks
Phase 2 - Meal Tolerance Test - Plasma Glucose
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in mmol/L
8 weeks
Phase 2 - Meal Tolerance Test - Plasma GLP-2
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in pg/ml.
8 weeks
Phase 2 - Meal Tolerance Test - Peptide YY
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in pg/ml.
8 weeks
Phase 2 - Meal Tolerance Test - Plasma Insulin
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. Measured in pg/ml.
8 weeks
Phase 2 - Meal Tolerance Test - Satiety (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 2 - Meal Tolerance Test - Hunger (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 2 - Meal Tolerance Test - Fullness (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 2 - Meal Tolerance Test - Desire to eat (VAS)
Tidsram: 8 weeks
Meal Tolerance Test - initiated in the fasting state with samples collected at T0 (fasting), T30, T60, T90, T120 & T180 mins following a standardised meal. VAS scales follow 0-100 measurement.
8 weeks
Phase 2 - Weight
Tidsram: 8 weeks
kg
8 weeks
Phase 2 - BMI
Tidsram: 8 weeks
kg/m2
8 weeks
Phase 2 - Hormonal Health - Leptin
Tidsram: 8 weeks
pg/ml
8 weeks
Phase 2 - Hormonal Health - Ghrelin
Tidsram: 8 weeks
pg/ml
8 weeks
Phase 2 - Inflammation - IL-6
Tidsram: 8 weeks
pg/ml
8 weeks
Phase 2 - Inflammation - IL-17
Tidsram: 8 weeks
pg/ml
8 weeks
Phase 2 - Safety - Blood Biomarkers - Red Blood Cell Count
Tidsram: 8 weeks
(10e12/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - White Blood Cell Count
Tidsram: 8 weeks
(10e9/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Hemoglobin
Tidsram: 8 weeks
(g/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Alanine Aminotransferase
Tidsram: 8 weeks
(IU/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Aspartate Aminotransferase
Tidsram: 8 weeks
(IU/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Serum Creatinine
Tidsram: 8 weeks
(umol/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - eGFR
Tidsram: 8 weeks
(mL/min/1.73 m²)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Sodium
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Potassium
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Total Cholesterol
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - LDL Cholesterol
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - HDL Cholesterol
Tidsram: 8 weeks
(mmol/L)
8 weeks
Phase 2 - Safety - Blood Biomarkers - LDL:HDL Cholesterol Ratio
Tidsram: 8 weeks
(no units)
8 weeks
Phase 2 - Safety - Blood Biomarkers - Fasting Glucose
Tidsram: 8 weeks
(mmol/L)
8 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Noel Caplice, MD, APC Microbiome Ireland
  • Studierektor: Adam Perlman, MD, MPH, Pendulum Therapeutics, Inc

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 september 2024

Primärt slutförande (Beräknad)

1 januari 2028

Avslutad studie (Beräknad)

1 april 2028

Studieregistreringsdatum

Först inskickad

1 april 2026

Först inskickad som uppfyllde QC-kriterierna

28 april 2026

Första postat (Faktisk)

5 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera